Fig. 2
From: Novel glycolipid agents for killing cisplatin-resistant human epithelial ovarian cancer cells
![Fig. 2](http://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs13046-017-0538-9/MediaObjects/13046_2017_538_Fig2_HTML.gif)
GAEL sensitivity of EOC cells grown in the presence of GLN (open circle) or MO-101 (closed diamond). a Dose–response curves for A2780-s (cisplatin sensitive) and A2780-cp (cisplatin resistant) cells. b Dose–response curves to GLN or MO-101 for two different primary EOC patient samples, EOC126 and EOC140. For A and B cells were exposed to drug for 48 h. Intersection with the dashed line approximates the CC50 value. Doses where there is a significant difference in cell viability between cells grown in the presence of GLN or MO-101 are indicated by an asterisk (*), p < 0.05